Cooley advised ERYTECH Pharma on a private placement of its ordinary shares to qualified investors in the US and Europe. Total gross proceeds to ERYTECH were approximately €70.5 million.
ERYTECH, based in Lyon, France, with US headquarters in Cambridge, MA, is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s ordinary shares are listed on Euronext Paris.
Cooley has advised with a team led by Marc Recht (Picture), Div Gupta and Brian Leaf.
Involved fees earner: Marc Recht – Cooley LLP; Div Gupta – Cooley LLP; Brian Leaf – Cooley LLP; Courtney Thorne – Cooley LLP; Mark Woodroffe – Cooley LLP; Evan Friedler – Cooley LLP; Francis Wheeler – Cooley LLP; Stephanie Gentile – Cooley LLP;
Law Firms: Cooley LLP;
Clients: Erytech Pharma;